Lianyu Zhou

Lianyu Zhou

Auto-generated profile, based on publicly available information

Lianyu Zhou

Department of Military Cognitive Psychology, School of Psychology, Army Medical University, Chongqing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2023 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
ZLZhe Liu
Zhe Liu
STShuai Tan
Shuai Tan
LZLianyu Zhou
Lianyu Zhou
LCLi Chen
Li Chen
MLMingfeng Liu
Mingfeng Liu
Da JiaDa Jia
Da Jia
Autism spectrum disorder (ASD) affects 1–2% of all children and poses a great social and economic challenge for the globe. As a highly heterogeneous neurodevelopmental disorder, the development of its treatment is extremely challenging. Multiple pathways have been linked to the pathogenesis of ASD, including signaling involved in synaptic function, oxytocinergic activities, immune homeostasis, chromatin modifications, and mitochondrial functions. Here, we identify secretagogin (SCGN), a regulator of synaptic transmission, as a new risk gene for ASD. Two heterozygous loss-of-function mutations in SCGN are presented in ASD probands. Deletion of Scgn in zebrafish or mice leads to autism-like behaviors and impairs brain development. Mechanistically, Scgn deficiency disrupts the oxytocin signaling and abnormally activates inflammation in both animal models. Both ASD probands carrying Scgn mutations also show reduced oxytocin levels. Importantly, we demonstrate that the administration of oxytocin and anti-inflammatory drugs can attenuate ASD-associated defects caused by SCGN deficiency. Altogether, we identify a convergence between a potential autism genetic risk factor SCGN, and the pathological deregulation in oxytocinergic signaling and immune responses, providing potential treatment for ASD patients suffering from SCGN deficiency. Our study also indicates that it is critical to identify and stratify ASD patient populations based on their disease mechanisms, which could greatly enhance therapeutic success.

25 July 2023 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
PJPeiyan Jiang
Peiyan Jiang
LZLianyu Zhou
Lianyu Zhou
LZLinyang Zhao
Linyang Zhao
XFXinghang Fei
Xinghang Fei
ZWZhifei Wang
Zhifei Wang
XFXiaotang Fan
Xiaotang Fan